Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ. Arend RC, et al. Among authors: birrer mj. Gynecol Oncol. 2020 Feb;156(2):301-307. doi: 10.1016/j.ygyno.2019.12.002. Epub 2019 Dec 20. Gynecol Oncol. 2020. PMID: 31870556 Clinical Trial.
Biomarkers in ovarian cancer: To be or not to be.
Arend R, Martinez A, Szul T, Birrer MJ. Arend R, et al. Among authors: birrer mj. Cancer. 2019 Dec 15;125 Suppl 24:4563-4572. doi: 10.1002/cncr.32595. Cancer. 2019. PMID: 31967683 Free article. Review.
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Rachmilewitz Minei T, Harats D, Wall JA, Foxall ME, Penson RT. Arend RC, et al. Among authors: birrer mj. Gynecol Oncol. 2020 Jun;157(3):578-584. doi: 10.1016/j.ygyno.2020.02.034. Epub 2020 Apr 5. Gynecol Oncol. 2020. PMID: 32265057 Free article. Clinical Trial.
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.
Doo DW, Meza-Perez S, Londoño AI, Goldsberry WN, Katre AA, Boone JD, Moore DJ, Hudson CT, Betella I, McCaw TR, Gangrade A, Bao R, Luke JJ, Yang ES, Birrer MJ, Starenki D, Cooper SJ, Buchsbaum DJ, Norian LA, Randall TD, Arend RC. Doo DW, et al. Among authors: birrer mj. Ther Adv Med Oncol. 2020 Apr 14;12:1758835920913798. doi: 10.1177/1758835920913798. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32313567 Free PMC article.
448 results